Clinical Trials Logo

Nausea and Vomiting clinical trials

View clinical trials related to Nausea and Vomiting.

Filter by:

NCT ID: NCT06282211 Recruiting - Nausea and Vomiting Clinical Trials

the Efficacy and Safety of Ondansetron Oral Soluble Pellicles

Start date: February 20, 2024
Phase: Phase 3
Study type: Interventional

The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy.

NCT ID: NCT06200168 Recruiting - Nausea and Vomiting Clinical Trials

Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer

Start date: December 20, 2023
Phase: Phase 3
Study type: Interventional

This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.

NCT ID: NCT05837156 Enrolling by invitation - Nausea and Vomiting Clinical Trials

A Clinical Study to Evaluate Cyclopofol Injection for the Prevention of Postoperative Nausea and Vomiting

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

This study uses cyclopropofol as a positive control and adopts a large sample, multicenter, randomized, single-blind, positive parallel control test design to explore the clinical application value of cyclopropofol in preventing postoperative nausea and vomiting.

NCT ID: NCT05690802 Recruiting - Nausea and Vomiting Clinical Trials

The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV

TSEPHCC
Start date: May 16, 2022
Phase: N/A
Study type: Interventional

To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.

NCT ID: NCT05533281 Recruiting - Nausea and Vomiting Clinical Trials

Efficacy of Three Antiemetics in Preventing Nausea and Vomiting

Start date: September 15, 2022
Phase: Early Phase 1
Study type: Interventional

To explore the effect of commonly used antiemetic drugs on reducing nausea and vomiting caused by intravenous tramadol injection, so as to reduce the incidence of nausea and vomiting in clinical use of tramadol and provide guidance for the clinical use of tramadol injection

NCT ID: NCT05016180 Recruiting - Nausea and Vomiting Clinical Trials

Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery

Start date: September 25, 2020
Phase: Phase 2
Study type: Interventional

Purpose: To explore and compare Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative nausea and vomiting and Early Outcome After Laparoscopic Bariatric Surgery To evaluate and examine TAPB can reduce the application of intraoperative and postoperative opioids and the duration of analgesia

NCT ID: NCT04560114 Completed - Nausea and Vomiting Clinical Trials

Effect of Inhaled Aromatherapy on Chemo-Induced Nausea Vomiting (NCVI): CINVAROM (Chemotherapy Induced Nausea Vomiting and AROMatherapy)

CINVAROM
Start date: December 14, 2020
Phase: Phase 2
Study type: Interventional

The investigator wish to provide a blend of two essential oils with comparable antiemetic properties; Peppermint essential oil (Mentha x Piperita) and lemon tree essential oil (Citrus Limon). Dry inhalation of these essential oils is safe, but effectiveness has not been determined. Studies on the subject present a questionable methodology. This is why we are proposing this study to measure the effectiveness of this mixture of essential oils on chemo-induced nausea and vomiting. This study is a first step before a possible study to compare the effects of essential oils with those of a placebo.

NCT ID: NCT03185156 Completed - Nausea and Vomiting Clinical Trials

The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate

Start date: June 28, 2017
Phase: Phase 4
Study type: Interventional

This is a randomized, placebo-controlled trail, the objective of this study is observation the effect of sub hypnotic dose of propofol for prevention of nausea and vomiting induced by hemabate during spinal anesthesia for elective cesarean section. The primary outcome is the presence of post-delivery intra-operative nausea and vomiting in parturients. The patients demographic characteristics, blood pressure, sensory block level, and the medications will be collected.

NCT ID: NCT02550119 Terminated - Nausea and Vomiting Clinical Trials

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Start date: April 19, 2006
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting.

NCT ID: NCT02116530 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Start date: August 2014
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies antiemetic therapy with olanzapine to see how well they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy. Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. Olanzapine may help prevent chemotherapy-induced nausea and vomiting by blocking brain receptors that appear to be involved in nausea and vomiting.